| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/02/2004 | WO2004073595A2 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use |
| 09/02/2004 | WO2004062645B1 Microspheres containing amphotericin b |
| 09/02/2004 | WO2004062551A3 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
| 09/02/2004 | WO2004054974A3 Piperidine derivatives as ccr5 antagonists |
| 09/02/2004 | WO2004052904A3 Novel semisynthetic macrolide antibiotics of the azalide series |
| 09/02/2004 | WO2004052313A3 Anti-infectives |
| 09/02/2004 | WO2004036224A3 Screening method |
| 09/02/2004 | WO2004022657A3 Increasing of the resorption of substances via skin and mucous membranes |
| 09/02/2004 | WO2003101375A3 Immunostimulatory oligonucleotides and uses thereof |
| 09/02/2004 | WO2003015697A3 Interleukin-2 mutants with reduced toxicity |
| 09/02/2004 | WO2003000200A3 β-2'-OR 3'-HALONUCLEOSIDES |
| 09/02/2004 | WO2002092589A3 Novel decalactones from associated fungi of marine sponges and their synthetic derivatives as medicaments |
| 09/02/2004 | US20040172687 Modified proteinase inhibitors |
| 09/02/2004 | US20040172112 Methods for treating prostatitis |
| 09/02/2004 | US20040171848 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 09/02/2004 | US20040171806 Modified hpv e6 and e7 genes and proteins useful for vaccination |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171802 Haemophilus influenzae antigens and corresponding dna fragments |
| 09/02/2004 | US20040171695 Guanylhydrazones useful for treating diseases associated with T cell activation |
| 09/02/2004 | US20040171689 Screening method using solid supports modified with self-assembled monolayers |
| 09/02/2004 | US20040171675 Antifungal agents of sordarin derivatives |
| 09/02/2004 | US20040171639 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 09/02/2004 | US20040171638 Chemokine receptor binding heterocyclic compounds |
| 09/02/2004 | US20040171637 anticancer agents; in admixture with one or more pharmaceutically acceptable carriers or diluents and a known chemotherapeutic agent |
| 09/02/2004 | US20040171626 having good to very good inhibitory activity against HCV polymerase; hepatitis C virus |
| 09/02/2004 | US20040171621 Novel crystalline forms of gatifloxacin and processes for preparation |
| 09/02/2004 | US20040171620 Nitrogen-containing bicyclic heterocycles for use as antibacterials |
| 09/02/2004 | US20040171618 Compounds as PDE IV and TNF-inhibitors |
| 09/02/2004 | US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer |
| 09/02/2004 | US20040171577 Aryl phosphate derivatives of d4T having anti-HIV activity |
| 09/02/2004 | US20040171568 oligonucleotide at least 29 nucleotides in length, wherein the anti-HIV activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 09/02/2004 | US20040171557 treating or educating said cells ex vivo in the presence of: intermediary metabolite; antigens or epitopes associated with said disease, or the immune-mediated inflammatory response; re-administering to said subject said treated or educated cells |
| 09/02/2004 | US20040171542 T1249 is a member of a new class of antiviral agents that inhibit virus/membrane fusion |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171528 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171527 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/02/2004 | US20040171526 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171523 Immunogenic glycopeptides, screening, preparation and uses |
| 09/02/2004 | US20040171522 Raise the intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171520 Melanocortin receptor-specific peptidomimetics |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171113 Antigens of group b streptococcus and corresponding dna fragments |
| 09/02/2004 | US20040171066 Template-fixed peptidomimetics with antimicrobial activity |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170997 used in drug screening for preventing or treating diseases associated with abnormalities in intracellular signal transduction; genetic engineering |
| 09/02/2004 | US20040170995 for drug screening in vitro for mitogen-activated protein kinase-activated protein kinase-2 modulators using expression libraries; genetic engineering; kits |
| 09/02/2004 | US20040170972 comprises DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine; includes use of serological diagnosis; genetic engineering |
| 09/02/2004 | US20040170969 GRF2 binding proteins and applications thereof |
| 09/02/2004 | US20040170961 for drug screening anticancer agents; solid phase synthesis; animal models; genetic engineering; kits |
| 09/02/2004 | US20040170959 Methods for identifying antiviral oligonucleotides |
| 09/02/2004 | US20040170712 Applying a Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170711 Medical effect of Jojoba oil in the treatment of anal diseases |
| 09/02/2004 | US20040170710 Treating vaginal diseases by applying Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170704 Process for the manufacture of a herbal composition |
| 09/02/2004 | US20040170691 Amoxycillin pellets |
| 09/02/2004 | US20040170652 Saponin inactivated mycoplasma vaccine |
| 09/02/2004 | US20040170649 uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact; autologous vaccines |
| 09/02/2004 | US20040170648 first valence adjuvanted with an aluminum hydroxide (especially Hepatite A); second valence contains a bacterial capsule polysaccharide with O-acetyl groups (especially typhoid fever valence formed by the polysaccharide Vi of the Salmonella typhi capsule); and phosphate, citrate or carbonate ions. |
| 09/02/2004 | US20040170644 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof |
| 09/02/2004 | US20040170639 administering by whole body spray a live avirulent derivative of an enteropathogenic bacterium that contains a recombinant gene encoding the protein, other than one that causes respiratory disease in birds; vaccines |
| 09/02/2004 | US20040170623 having a concentration of at least 50 mg/ml of the antibody and containing an acidic component; nasal sprays and slow release formulations drying or freeze-drying |
| 09/02/2004 | US20040170620 Selected antibody compositions for binding to aminophospholipids |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | US20040170573 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 09/02/2004 | US20040170569 Dosage forms that rapidly produces peak plasma concentrations; heating a thin layer of the drug on a solid support to form a vapor; and passing air through the heated vapor to produce aerosol particles having less than 10% drug degradation products |
| 09/02/2004 | CA2516328A1 Inhibitors of hepatitis c virus, compositions and treatments using the same |
| 09/02/2004 | CA2516235A1 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| 09/02/2004 | CA2516130A1 Assay for the identification of protein sic inhibitor |
| 09/02/2004 | CA2515984A1 Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them |
| 09/02/2004 | CA2515939A1 Novel compounds |
| 09/02/2004 | CA2515679A1 Glycinamide derivative for inhibiting hiv replication |
| 09/02/2004 | CA2515610A1 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use |
| 09/02/2004 | CA2515567A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/01/2004 | EP1452541A1 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof |
| 09/01/2004 | EP1452534A1 Pleuromutlin derivatives as antimicrobials |
| 09/01/2004 | EP1452181A1 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/01/2004 | EP1451338A1 Recombinant antibodies for the detection and neutralization of anthrax toxin |
| 09/01/2004 | EP1451333A2 Ul16 binding protein 4 |
| 09/01/2004 | EP1451329A2 Genetic vaccine against human immunodeficiency virus |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451305A2 Epitope synchronization in antigen presenting cells |
| 09/01/2004 | EP1451226A1 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 09/01/2004 | EP1451222A2 Novel proteins with il-6 inhibiting activity |
| 09/01/2004 | EP1451212A2 Structural and cytoskeleton-associated proteins |
| 09/01/2004 | EP1451210A2 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451194A2 Preparation of levofloxacin and forms thereof |
| 09/01/2004 | EP1451191A1 Thioether substituted imidazoquinolines |
| 09/01/2004 | EP1451190A1 Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof |
| 09/01/2004 | EP1451187A1 Amide substituted imidazopyridines |
| 09/01/2004 | EP1451186A2 Urea substituted imidazopyridines |
| 09/01/2004 | EP1451184A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451183A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451182A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451181A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451177A1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine |
| 09/01/2004 | EP1451164A2 Amide derivatives having improved solubility |
| 09/01/2004 | EP1451162A1 Substituted diphenyl heterocycles useful for treating hcv infection |
| 09/01/2004 | EP1451156A1 4-aminoquinoline compounds |
| 09/01/2004 | EP1451144A1 Compositions for treating acne comprising phytandiol amine |